MedTrace Logo

Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients

NCT05829317 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-09-22

No results posted yet for this study

Summary

A double-blind, multi-centre, randomized, placebo-controlled, feasibility pilot trial in the prevention of new onset atrial fibrillation of critically ill patients admitted to an ICU.

Conditions

  • Critical Illness
  • New Onset Atrial Fibrillation

Interventions

DRUG

Magnesium sulfate

Intravenous Magnesium sulfate

DRUG

Placebo

0.9% NaCl

Sponsors & Collaborators

  • Southeastern Ontario Academic Medical Organization (SEAMO)

    collaborator UNKNOWN

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Dr. Stephanie Sibley

    lead OTHER

Principal Investigators

  • Stephanie Sibley, MD · Queen's University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-20
Primary Completion
2028-03-01
Completion
2028-07-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05829317 on ClinicalTrials.gov